Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice

References

• National Eye Institute. Age-Related Macular Degeneration (AMD). Bethesda, MD: National Institutes of Health; 2021. Available from: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration. Accessed February 15, 2023.
   Google Scholar
• BrightFocus Foundation. Age-related macular degeneration: facts & figures. Clarksburg, MD: BrightFocus Foundation; 2023. Available from: https://www.brightfocus.org/macular/article/age-related-macular-facts-figures. Accessed August 31, 2023.
   Google Scholar
• Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1202–1208. doi:10.1001/jamaophthalmol.2022.4401
   PubMed Web of Science ®Google Scholar
• Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3(1):34. doi:10.1186/s40662-016-0063-5
   PubMedGoogle Scholar
• Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133. doi:10.1186/s12967-023-03937-7
   PubMed Web of Science ®Google Scholar
• Arepalli S, Kaiser PK. Pipeline therapies for neovascular age related macular degeneration. Int J Retina Vitreous. 2021;7(1):55. doi:10.1186/s40942-021-00325-5
   PubMedGoogle Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, Phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi:10.1016/S0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• Vabysmo [Prescribing Information]. Last updated January 2023. South San Francisco, CA: Genentech Inc.
   Google Scholar
• Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T. Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology. 2016;123(4):876–883. doi:10.1016/j.ophtha.2015.12.001
   PubMed Web of Science ®Google Scholar
• Vennedey V, Danner M, Evers SM, et al. Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. Patient Prefer Adherence. 2016;10:993–1002. doi:10.2147/PPA.S101584
   PubMed Web of Science ®Google Scholar
• Joko T, Nagai Y, Mori R, et al. Patient preferences for anti-vascular endothelial growth factor treatment for wet age-related macular degeneration in Japan: a discrete choice experiment. Patient Prefer Adherence. 2020;14:553–567.
   PubMed Web of Science ®Google Scholar
• Ozdemir S, Finkelstein E, Lee JJ, et al. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLoS One. 2022;17(8):e0272301. doi:10.1371/journal.pone.0272301
   PubMed Web of Science ®Google Scholar
• Lanzetta P, Loewenstein A. Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–1273. doi:10.1007/s00417-017-3647-4
   PubMed Web of Science ®Google Scholar
• Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023;37(1):6–16. doi:10.1038/s41433-022-02020-7
   PubMed Web of Science ®Google Scholar
• Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36(8):1418–1431. doi:10.1097/IAE.0000000000001142
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24(2a Suppl):S3–S15. doi:10.18553/jmcp.2018.24.2-a.s3
   PubMedGoogle Scholar
• Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–146. doi:10.1016/j.preteyeres.2017.12.002
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072. doi:10.1185/03007990802457040
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. doi:10.1136/bmjopen-2015-010352
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380. doi:10.2147/DMSO.S120101
   PubMed Web of Science ®Google Scholar
• Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;1:1–9.
   Google Scholar
• US Department of Health and Human Services [internet]. Summary of the HIPAA Privacy Rule. Washington, DC; 2003. Available from: http://www.hhs.gov/sites/default/files/privacysummary.pdf. Accessed June 8, 2023.
   Google Scholar
• European Pharmaceutical Market Research Association (EphMRA). Code of Conduct. Basel, Switzerland; 2022. Available from: https://www.ephmra.org/code-conduct-aer. Accessed June 8, 2023.
   Google Scholar
• US Department of Health and Human Services. Health Information Technology for Economic and Clinical Health (HITECH) Act. Washington, DC; 2009. Available from: https://www.hhs.gov/hipaa/for-professionals/special-topics/hitech-act-enforcement-interim-final-rule/index.html. Accessed June 8, 2023.
   Google Scholar
• Ashraf M, Banaee T, Silva FQ, Singh RP. Switching anti-vascular endothelial growth factors in refractory neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018;49(3):166–170. doi:10.3928/23258160-20180221-03
   PubMed Web of Science ®Google Scholar
• Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143(4):679–680. doi:10.1016/j.ajo.2007.02.024
   PubMed Web of Science ®Google Scholar
• Lucentis [Prescribing Information]. South San Francisco, CA: Genentech, Inc.; 2023.
   Google Scholar
• Gemenetzi M, Patel PJ. A systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-related macular degeneration. Ophthalmol Ther. 2017;6(1):79–92. doi:10.1007/s40123-017-0087-5
   PubMedGoogle Scholar
• Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2181–2192. doi:10.1007/s00417-020-05048-1
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Rapuano SB, Boyer D. A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States. Am J Ophthalmol. 2021;223:405–429. doi:10.1016/j.ajo.2020.07.010
   PubMed Web of Science ®Google Scholar
• Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127(1):1.
   PubMed Web of Science ®Google Scholar
• Amissah-Arthur KN, Panneerselvam S, Narendran N, Yang YC. Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration. Eye (Lond). 2012;26(3):394–399. doi:10.1038/eye.2011.335
   PubMed Web of Science ®Google Scholar
• Jhaveri CD, Glassman AR, Ferris FL, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med. 2022;387(8):692–703. doi:10.1056/NEJMoa2204225
   PubMed Web of Science ®Google Scholar
• American Society of Retina Specialists [internet]. Physician choice of medication. Chicago, IL; 2013. Available from: https://www.asrs.org/advocacy/physician-choice-of-medication. Accessed February 17, 2023.
   Google Scholar
• Hassan T. Step therapy undermines physician choice of AMD treatment. Conshohocken, PA: Retina Today; 2013. Available from: https://retinatoday.com/articles/2013-oct/step-therapy-undermines-physician-choice-of-amd-treatment. Accessed February 17, 2023.
   Google Scholar
• Saunders C, Byrne CD, Guthrie B, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30(3):300–308. doi:10.1111/dme.12047
   PubMed Web of Science ®Google Scholar
• Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304. doi:10.2147/JMDH.S160029
   PubMed Web of Science ®Google Scholar